BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 32533433)

  • 21. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Okita Y; Hirao M; Etani Y; Kumanogoh A; Okada S; Nakata K
    Sci Rep; 2022 Jan; 12(1):134. PubMed ID: 34997059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
    Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
    Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
    Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
    Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA.
    Amrhein J; Drynda S; Schlatt L; Karst U; Lohmann CH; Ciarimboli G; Bertrand J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32927842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection.
    Faquetti ML; Grisoni F; Schneider P; Schneider G; Burden AM
    Sci Rep; 2022 May; 12(1):7843. PubMed ID: 35551258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
    Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
    Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baricitinib and tofacitinib in patients with rheumatoid arthritis: results of regular clinical practice.
    González-Freire L; Giménez-Candela RM; Castro-Luaces S; Veiga-Villaverde AB; Crespo-Diz C
    Farm Hosp; 2021 Jun; 45(4):165-169. PubMed ID: 34218760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
    Scheepers L; Yang Y; Chen YL; Jones G
    Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
    Fitton J; Melville AR; Emery P; Nam JL; Buch MH
    Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.
    Hoisnard L; Lebrun-Vignes B; Maury S; Mahevas M; El Karoui K; Roy L; Zarour A; Michel M; Cohen JL; Amiot A; Claudepierre P; Wolkenstein P; Grimbert P; Sbidian E
    Sci Rep; 2022 May; 12(1):7140. PubMed ID: 35504889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
    Mori S; Ogata F; Tsunoda R
    Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data.
    Barbulescu A; Askling J; Chatzidionysiou K; Forsblad-d'Elia H; Kastbom A; Lindström U; Turesson C; Frisell T
    Rheumatology (Oxford); 2022 Oct; 61(10):3952-3962. PubMed ID: 35134119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching.
    Dhir B; Meena SK; Sardana K; Sharath S
    Pediatr Dermatol; 2024; 41(1):139-140. PubMed ID: 37495552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [JAK Inhibitors in Rheumatology].
    Witte T
    Dtsch Med Wochenschr; 2019 Jun; 144(11):748-752. PubMed ID: 31163474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Symptomatic elevation creatine kinase following treatment of rheumatoid arthritis with baricitinib.
    Anjara P; Jiang M; Mundae M
    Clin Rheumatol; 2020 Feb; 39(2):613-614. PubMed ID: 31782014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
    Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Inoue Y; Fujino Y; Tanaka Y
    Ann Rheum Dis; 2021 Sep; 80(9):1130-1136. PubMed ID: 33827788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib.
    Dasic G; Jones T; Frajzyngier V; Rojo R; Madsen A; Valdez H
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System.
    Liu T; Gao R; Li L; Wu B; Wu F
    Int J Clin Pharm; 2023 Dec; 45(6):1483-1491. PubMed ID: 37606843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.